A Phase 2 interventional study of AR882 Dose 1 and AR882 Dose 2 in Gout, Arthritis, Gouty and Hyperuricemia, sponsored by Arthrosi Therapeutics. Completed at 23 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-05-12.
Sponsored by Arthrosi Therapeutics (part of Swedish Orphan Biovitrum) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Arthritis, Gouty with a site in United States — 3 open to participants now, 4 under way, 1 of them phase 3. Arthritis, Gouty · United States.
Among the 15 studies in Arthritis, Gouty with a site in United States, this one is the 9th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2021, is one of 6 in phase 2, and was the 8th registered.
47 studies on the registry are indexed under Arthritis, Gouty; 16 are open to participants now.
Browse Arthritis, Gouty studies →3 of the 15 studies in Arthritis, Gouty with a site in United States are open now. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18–90
Olatec Therapeutics, Inc. · Sites in United States, France, Israel and 2 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 10 Arthritis, Gouty studies recruiting now, 8 (80%) set no upper age limit and 1 (10%) stops at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 7 · Phase 3 6 · Phase 4 1
First in 2008; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 140 is close to the median of 140 across 35 interventional studies indexed under Arthritis, Gouty.
Median enrollment 225 across the 14 interventional studies, 843 across the 1 observational. Of the 11 that completed or were terminated, 6 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 15 have an industry lead sponsor. The 9 most frequent:
This study is registered under Arthrosi Therapeutics, one of the names counted as Swedish Orphan Biovitrum. Under that name alone:
Arthrosi Therapeutics is the lead sponsor of 10 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Swedish Orphan Biovitrum has 5 studies filed under Arthritis, Gouty — fewer than ten, so there is no comparison to draw.
3 of the studies in Arthritis, Gouty with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05658575Phase 3Olatec Therapeutics, Inc.Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare | 2026-12-31 |
| NCT07116746Arthrosi TherapeuticsEvaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients | 2026-11 |
| NCT07346079Massachusetts General HospitalPurified Cortrophin® Gel Efficacy and Safety Study of 2 Dose Levels in Patients With Acute Gout Flares | 2027-08-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 15 studies in Arthritis, Gouty with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 weeks.
47 studies on the registry are indexed under Arthritis, Gouty; 16 are open to participants now.
This study's enrollment of 140 is close to the median of 140 across 35 interventional studies indexed under Arthritis, Gouty.
Browse Arthritis, Gouty studies →Arthrosi Therapeutics is the lead sponsor of 10 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
First submitted before Arthrosi Therapeutics became part of Swedish Orphan Biovitrum.
Compared within Arthritis, Gouty, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Gout. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AR882 Dose 1 x 12 weeks
Drug: AR882 Dose 1
AR882 Dose 1 x 2 weeks, then Dose 2 x 10 weeks
Drug: AR882 Dose 1 · Drug: AR882 Dose 2
AR882 matching placebo x 12 weeks
Drug: Placebo
Solid Oral Capsule
Solid Oral Capsule
Matching Solid Oral Capsule Placebo
Serum urate (uric acid) (sUA) level < 6 mg/dL following 6 weeks of dosing
Comparison of the treatment groups for the proportion of patients with serum urate (uric acid) (sUA) level \< 6 mg/dL following 6 weeks of dosing
Time frame: 6 weeks
sUA levels < 5, < 4, and < 3 mg/dL
Comparison of the treatment groups for proportion of patients whose sUA levels are \< 5, \< 4, and \< 3 mg/dL
Time frame: 6 weeks
Incidence of Adverse Events
Treatment Emergent Adverse Events and Serious Adverse Event incidence.
Time frame: 14 weeks
Maximum Observed Plasma Concentration (Cmax)
Plasma samples will be collected to assess plasma concentrations at a series of timepoints to derive Cmax.
Time frame: 12 weeks
Time to observed Cmax (Tmax)
Plasma samples will be collected to assess plasma concentrations at a series of timepoints to derive Tmax.
Time frame: 12 weeks
Area under the plasma concentration-time curve (AUC)
Plasma samples will be collected to assess plasma concentrations at a series of timepoints to derive AUC.
Time frame: 12 weeks
Ran from Nov 2021 to primary completion in Nov 2022, 12 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AR882